RPG Life Sciences Limited — Interim / Quarterly Report 2022

Jul 28, 2021

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071 , India Tel: +91-22-25292152-55 Fax: +91 -22-25297423

July 28, 2021

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

BSE Limited Corporate Relationship Department Floo 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended June 30, 2021

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2021 which were approved by the Board of Directors of the Company, at its meeting held on July 28, 2021 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar Head – Legal & Company Secretary

Encl: as above

BS R & Co. LLP

Chartered Accountants

14th Floor, Central Wing B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Limited review report on unaudited quarterly financial results of RPG Life Sciences Limited under regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 June 2021 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accmmting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Infonnation Perfonned by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perfonn the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not perfonned an audit and accordingly, we do not express an audit opinion.
• 1. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not su~jected to audit.
• 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance \vith applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

ForB SR& Co. LLP Chartered Accountants Firm's Registration No: 101248W/W- 100022

Himanshu Chapsey Partner Membership No: 105731 ICAI UDIN: 21105731AAAAEX3796

Place: Mumbai Date: 28 July 2021

Hcgistc rc<l Office:

1'1lh Floor. Cenlral B W ng and North C Wing, Nesco IT Park 4. Nesco Cenw1, Western [xµrnss 1 !iuhy,:ay, Goreuoon (Cast), Mumbai - 400063

D Sn & Co. (o µ.:utne,hiµ forn with ntigb11atto11 No . 0/\61223) rnnve1te<l ir1to D S fl & Co. LLP l,1 I imitrl I i,1h:lity P;irtnr.rship with 11 P Hcgistr.ition No. AAf18181) with cffcr.t from Octohcr 14, / 0 1'.i

RPG LIFE SCIENC ES LIM ITED

Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: I 91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglitesciences.com CIN : L24232MH2007PLC169354

(Rs. in Lakhs)

		Quarter endedYear ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
Particulars		(Unaudited)	(Audited)(Refer Note 2)	(Unaudited)	(Audited)
1	Revenue from Operations	10,813	9,276	9,165	38,914
2	Other Income	41	30	45	91
3	Total Income	10,854	9,306	9,210	39,005
4	Expenses
	Cost of Materials Consumed(a)	2,087	1,806	1,914	8,575
	(b)Purchases of Stock-in-Trade	1,484	1,205	1,505	5,036
	Changes in Inventories of Finished Goods, Work-in(C)
	Progress and Stock-in-Trade	(76)	252	(492)	(501)
	(d)Employee Benefits Expense	2,360	2,280	2,308	9,466
	(e)Finance Costs	13	9	31	79
	(f)Depreciation and Amortisation Expense	396	392	416	1,647
	(g)Other Expenses	2,663	2,467	2,245	9,345
	Total Expenses	8,927	8,411	7,927	33,647
5	Profit before tax (3-4)	1,927	895	1,283	5,358
6	Income tax expenses
	a. Current Tax	578	295	411	1,715
	b. Deferred Tax	(9)	(92)	(34)	(357)
7	Profit for the period (5-6}	1,358	692	906	4,000
8	Other Comprehensive Income
	(i) Items that will not be reclassified to Profit or Loss	(4)	2	(6)	( 16)
	(ii) Income tax relating to items that will not bereclassified to Profit or Loss	1	( 1)	2	4
	Other Comprehensive Income Net of Tax	(3)	1	(4)	(12)
9	Total Comprehensive Income for the period (7+8}	1,355	693	902	3,988
10	Paid-up Equity Share Capital( Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11	Other Equity				20,322
12	Earnings per Share (of Rs. 8/- each) (not annualised forthe quarter):
	(a)Basic	8.21	4.18	5.48	24.19
	(b)Diluted	8.21	4.18	5.48	24.19

Statement of Financial Results for the quarter ended 30th June 2021

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 28, 2021.

2 Figures for the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year ended on that date and the published year to date figures upto the end of the third quarter of the said financial year. Also, the figures upto the end of the third quarter had only been subjected to limited review.

3 The Company operates in only one reportable business segment i.e., Pharmaceuticals.

Foe RPG ~ eaces um;ted

Yugal Sikri Managing Director Mumbai, July 28, 2021

Ttn- : F.,,o~m, ic ·n ~I t"); An <»>RPG Company